Skip to content

Immediate Postpartum Insertion of Contraceptive Intrauterine Devices

Immediate Postpartum Insertion of Kyleena vs Mirena Contraceptive Intrauterine Devices

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03657602
Enrollment
28
Registered
2018-09-05
Start date
2019-12-15
Completion date
2023-01-15
Last updated
2023-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception

Brief summary

In this randomized trial, investigators intend to determine the expulsion and discontinuation rate of immediate postpartum intrauterine devices in the patient population of the University of Oklahoma Women's Healthcare Specialists Clinic (OUWHSC).

Detailed description

Between 40-57% of women report having unprotected intercourse prior to the 6 week postpartum visit. Immediate postpartum long-acting reversible contraception (LARC) is extremely important in preventing short-interval and unintended pregnancies. The postpartum period is an excellent time for intrauterine device (IUD) or implant insertion as women are often highly motivated to prevent unwanted pregnancies at this time. Per the American College of Obstetrics and Gynecology (ACOG), expulsion rates for immediate postpartum IUD insertion are higher than for interval or post-abortion insertion. Despite the higher expulsion rate of immediate postpartum IUD placement over interval placement, cost-benefit analysis data strongly suggest the superiority of immediate placement in reduction of unintended pregnancy, especially for women at greatest risk of not attending the postpartum follow-up visit. This study will randomly allocate participants one to one to the Kyleena or the Mirena IUD group, and participants will be blinded to allocation of groups. Participants will follow up at routine postpartum visit within 4 weeks of delivery, and a second follow up will be performed at 10 weeks. Ultimately, this study will attempt to provide more detailed information on the difference of rates of expulsion and discontinuation of the different-sized Mirena and Kyleena intrauterine devices.

Interventions

DRUGKyleena Intrauterine System

Participant will be randomly allocated to this intervention

DRUGMirena Intrauterine System

Participant will be randomly allocated to this intervention

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Participant will be blinded to group assignment

Intervention model description

Participants will be randomly allocated one to one to the Kyleena or Mirena group and assessment will occur in parallel

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 years or older * desire an intrauterine device as postpartum contraception * want to avoid pregnancy for at least 1 year * are currently pregnant * desire immediate postpartum IUD insertion.

Exclusion criteria

* known uterine or cervical anomaly * untreated cervical infection * untreated cervical infection * pelvic infection within 3 months of the study * recent (within last 3 months) or active intrauterine infection * genital bleeding of unknown etiology * history of postpartum or postabortal sepsis * cervical cancer or carcinoma in suit * plan to leave Tulsa area within 10 weeks postpartum * allergy to device ingredients

Design outcomes

Primary

MeasureTime frameDescription
Expulsion of intrauterine contraceptionwithin 10 weeks of placementIUD string check and ultrasound check

Secondary

MeasureTime frameDescription
Discontinuation of intrauterine contraceptionThrough study completion, an average of 1 yearDate IUD is removed

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026